Trustees. Annual Report for the period i Perlod start date Perlod end date From Section A Reference and administration details Charlty rbamo United lfjngdom Photopheresis So¢iety Othor namos charlty18 kn(Mn by . R•gi8tsr•d Charfty numbar (If any) 1178321 CharW8 prlndpal addr•88 The Rotherham NHS Foundatton Trust Moorgate Road Rotherham Postcode S60 2UD Names of tho charlty trustO08 who manago the charlty. Dat•• acknd If nat for whol• ' Thi•t•• nan Offlv {Ifany) N•rM of p•r•on (or body) ontltl•d nt tru•ts• If Dr Arun Affred Prof AGennery Treasurer President 10 11 12 13 14 15 17 18 19 20 Names of tho tru8ts08 for tho charlty, If anyg (for oxamplo, any cu8todlan'trust••8) Nam• Dat•8 act•d If not for whol• .TAR Marth 2012 Names and addresses of advisers (Optional information) e of advlser Namo Address Name of chlef executlve or names of senior staff members (Optional inforniation) Section B Structure, overnance and mana ement Doscrlptlon of tho charlty's trusts Constitution Type of governing document How the charity is constituted (eg. trusl, association, company) cio Trustee selection methods Appolnted by UK Photoph8r8sis Society members Iv¥. ijvyvii kry ijy I Addltlonal g￿rnance issu88 Ioptlonal Infomiatlon) You may choose to includ8 additional information, where r81evanC about: policies and procedures adopted for the induction and training of trustees- the charity's organisational structure and any wider ne￿Ork V￿th which the charity relationship with any related parties., trustees. consid8ration of major risks and the System and procedures to manage them. Section C Ob'ectives and activities To advance health by promoting the knowledge of Photopheresis, stimulate research in this field, and disseminate knowledge at meetings, via publications and guidelinès and work to develop best stsndards in clinical practice for the advancement of care to the health benefit of our patients. The So¢iety would wish to represent the application of Photopheresis to UK Heatth¢ar8 organisations and facilitat8 collaboration with International organisations to foster research and medical advance in this field. This would indude but not b8 limited to provisions of grants to hel achieve the ob'ectives of the Socie Summary of tha objacts of the charlty set out in its g0￿mIng document TAR March 2012 Annual education meetlng Award of research grant in field of Photopher88is Summary of tho maln actlvftle8 undortakon for the publ1¢ bonefft In relatlon to th•8• objocts (Include wlthln this 8•Ctlon the statutory doclaration that truste￿ hav• had rngard to th8 guldancè Issued by the Charty Commission on public benofk) Addltlonal d•tsll$ of objectlves and actlvltlos (Opuonal Inforniatlon) You may ch0080 to include further $tst8m8nts. where relevant, about: policy on grantmaking: policy programma related Investment: contrlbution made by w)lunt88rs. TAR Marth 2012 Section D Achievements and performance Annual educational meeting held on October 5th ,2023 Mallinckrodt Sponsored Session 10'.00 - 10.'40 To improve overall survival in acute GVHD by applying ECP Dr. Melhem M. Solh. Northside Hospital, Atlanta, Georgia Sanofi Sponsored Session 10:40 - 11.20: The dual role of ROCK2 inhibitors and ECP in treating GVHD Dr Corey Cutler, Dana-Farber Cancer Institute, Boston. Massachusetts 11:20 - 11:40 11.40 - 13.00 Nurse-led Symposium.. Vascular access. Vascular Issues + Audit Ms Anne McDermott, 13.'00 - 14:00 Lunch and Poster viewing 14'.00 - 14.'45 UKPS Business meeting 14.'45 - 15.'30 E-CLAD Trial: Update and progress Professor And￿W Fisher, Newcastle University 15:30 - 15:45 Aft8moon coff68 break 15:45 16.15. E-CL4D: Immunology update Mr Steven Bolton, New¢8slle University 16.'15- 16:45 Investigating Extracellular Vesicles in ECP Response in Patients with GVHD Dr Rachel Crossland, Newcastle University 16.'45 - 17.'00 Summary & Close Summary of the maln achlevemonts of tho charlty during the yèar Research Grants.. 'Mechanisrns of action of ECP therapy for GVHD, focusing on the role of Ev-derived microRNAs°. Ivhich aims to further understanding thè molecular mechanisms of ECP action. Includlng EV microRNAs, as w811 as idèntrfy biomark8rs for using ECP as first line or pre-emptive GVHD therapy.. Dr Rathel Crossland new¢astl8 Unlversity TAR March 2012 Section E Financial review Brf•f statem•nt of lh• charftys pollcy on r•8•rv Tha charity's finance8 are presented regularfy at the Annual meeting ar)d reviewed with regards to holding adequate appropriate resource8 Deta118 of any fund8 matsrfally In doficlt None Furth•r Ilnanclal r•vl•w d•tall8 (Optlonal infomiatlon) You may ch008• to Include additional Infomation, where relevant abouL' the charity's prlncipal sources of funds (including any fundraising); how expenditure has supported the key objectives of the charity; Investment policy and objectlves Including any 8thical Investment policy adopted. Section F Other optional information Section G Declaration The tru8tOo8 do¢lara that they hav8 approvod tho tru8ts88' report abov8. Slgn•d on bohalf of th• ¢harW8 trusts Slgnatur•(8) Full namo(8) Po8ltlon (09 Socr•tsry, Chair, Dr Arun Alfred Treasurer 29111124 TAR March 2012 ## **Statement of accounts for the UKPS for April 2023 to March 2024 presented to Board** ## **Charity registration number: 1178321** 1/4/23: £93,958 20/7/23: Income £20,000 Therakos UL Ltd-sponsorship for annual meeting 6/10/23: £4,120 Friends House venue for annual meeting 4/1/24: Income £7,500 Sanofi Ltd – annual meeting sponsorship 11/1/24 £14,691.14 Newcastle University Research grant Account charges: £60.00 Current balance 31/3/24: £102,587.26 Dr Arun Alfred 29/11/24 Treasurer UKPS CHARITY COMMISSION FOR ENGLAND AND WALES Independent examiner's report on the accounts Section A Independent Examiner's Report Roport to tho trustoo81 mombors of CharKy UNITED KIN&Po￿ FllvicPhllSSl£ Sc ry On accounts for the year ended. Charlty no (If any) 11188LI Sot out on pag08 {rem6Yni)c( to IllLiude Ihe paoe numbers of 8dditirJri'.i $haetsl I report to the trusfees on my examlnatlon of the accounts of th8 8bove . charity (Ihe Trust.) for the year ended 8:,1 .'0 & i R88ponslbllltlo8 and As the charity trustees of th8 Trust, YOU are responsible for th8 preparatlon ba818 of reF)Ort of the ac￿untS in accordance wlth the requirements of the Charities Act 2011 ('the Acr). I report in respect of my 8X8mlnation of the Tru8f8 accounts carried out under section 145 of the 2011 Act and In carying out my examination.. I have follow8tl the applicable Dlrections given by the Charfty Comlnission under sectioh 145(5Xb) of the Act. I have completed my examination. I confirm that no materlal matters hav6 corne to my attention {other than that disclosed belo￿ ") in ￿nnectIOn wlth the examlnatlon whloh glves me cause to believe that in, any material respect.. accountlng records were not kept in accordance with section 130 of the Act or the accounts do not accord with the 8c¢¢iunting records Independent oxamlnorfs stat•m•nt I have no concems and have come across no ott￿r matters In connection with the examination to which attention should be drawn in order to enable a proper understsnding of the accounts to b8 reached. Ple8 elete the wor in the kets rflhey do not apply. Slgnod: Date: Nam•: Relevart professlonal .quallflcatlon{8) or body (If any): Addr088: IER October 2018 Section B Disclosure Only complete if the examiner needs to highlight matters of concem (see CC32, Independent examination of charity accounts: directions and guidance for examiners). Glve hore brlef detalls of any items that the oxaminer wishes to dlsclose. IER Octobgr 2018